Portugal vs South Africa: Share of the population living with HIV receiving antiretroviral therapy
Portugal
82.0%
in 2017
South Africa
80.6%
in 2024
Portugal rank
47th
South Africa rank
50th
Share of the population living with HIV receiving antiretroviral therapy over time
- Portugal
- South Africa
How they compare
Portugal currently reports 82.0% against 80.6% in South Africa, a difference of 1.4%.
The two have swapped places 1 time across 28 shared years of data; in 1990 it was South Africa ahead.
Portugal ranks 47th and South Africa ranks 50th of 149 countries.
Portugal has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Portugal | South Africa | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 2.4% | 0.0% | 2.4% | Portugal |
| 2000s | 32.3% | 5.6% | 26.7% | Portugal |
| 2010s | 65.1% | 46.4% | 18.7% | Portugal |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Portugal or South Africa?
- Portugal, at 82.0% against 80.6% in South Africa as of 2017.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Portugal and South Africa?
- 1.4%, with Portugal ahead.
- How many years of comparable data are there for Portugal and South Africa?
- 28 years are reported by both, from 1990 to 2017.
- How do Portugal and South Africa rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Portugal ranks 47th and South Africa ranks 50th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.